[1]刘丽,卲天朋,曹建民,等.动态对比增强MRI对结肠癌肝转移瘤TACE治疗前后微循环灌注改变及近期疗效评价[J].介入放射学杂志,2016,(06):501-505.
　LIU Li,SHAO Tian-peng,CAO Jian-min,et al.Application of DEC-MRI in evaluating the changes of microcirculation perfusion of liver metastasis from colon cancer after TACE treatment and the short-term effect [J].journal interventional radiology,2016,(06):501-505.
点击复制

动态对比增强MRI对结肠癌肝转移瘤TACE治疗前后微循环灌注改变及近期疗效评价 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2016年06期
页码:
501-505
栏目:
肿瘤介入
出版日期:
2016-06-25

文章信息/Info

Title:
Application of DEC-MRI in evaluating the changes of microcirculation perfusion of liver metastasis from colon cancer after TACE treatment and the short-term effect

作者:
刘丽; 卲天朋; 曹建民; 卢光明; 许健
Author(s):
LIU Li;  SHAO Tian-peng;  CAO Jian-min;  LU Guang-ming;  XU Jian
Department of Medical Imaging, Nanjing General Hospital of Nanjing Military Area Command, Nanjing, Jiangsu Province 210002, China
关键词:
【关键词】结肠癌肝转移瘤;  经导管动脉化疗栓塞术;  磁共振动态增强扫描;  肿瘤血管生成;  微循环灌注
文献标志码:
A
摘要:
【摘要】目的探讨结肠癌肝转移瘤经导管动脉化疗栓塞（TACE）治疗前后动态对比增强磁共振成像（DCE-MRI）各定量参数的变化及其对预后评估的价值。方法对21例经病理证实为低分化腺癌的结肠癌肝转移患者分别于TACE术前及术后进行常规MRI和DCE-MRI扫描。以两腔室模型为基础,计算出定量血流动力学参数（Ktrans、Kep、Ve）。比较TACE术前、术后各参数的变化；分别探讨患者近期疗效与TACE术后DCE-MRI各项参数的相关性；并比较不同预后患者TACE术后各参数的差别。结果TACE术后肿瘤组织的Ktrans、Kep 及Ve值呈下降趋势,且术前术后差别有统计学意义。DCE-MRI各项参数与CEA、CA125、CA199和CA242值无明显相关性。术后近期疗效评估示完全缓解3例（14.3%）,部分缓解11例（52.4%）,总有效率（RR）66.7%,疾病控制率（DCR）90.5%。其中RR、PCR 均与术后Ktrans值呈正相关（r=0.526, P=0.005; r=0.557, P=0.006）,但与Kep、Ve值无明显相关性。 结论结肠癌肝转移瘤TACE治疗前后DCE-MRI各定量血流动力学参数变化显著,术后肿瘤组织中的Ktrans值可作为结肠癌肝转移TACE治疗早期疗效评估指标,为结肠癌肝转移瘤个体化治疗和治疗方案的修正提供依据,其远期疗效与DCE-MRI定量参数的相关性需进一步深入研究。


参考文献/References:

［1］Kim JH. Chemotherapy for colorectal cancer in the elderly［J］. World J Gastroenterol, 2015, 21: 5158-5166.

［2］Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012［J］. Int J Cancer, 2015, 136: E359-E386.

［3］Page AJ, Weiss MJ, Pawlik TM. Surgical management of noncolorectal cancer liver metastases［J］. Cancer, 2014, 120: 3111-3121.

［4］Akgul O, Cetinkaya E, Ersoz S, et al. Role of surgery in colorectal cancer liver metastases［J］. World J Gastroenterol, 2014, 20: 6113-6122.

［5］Sadahiro S, Suzuki T, Ishikawa K, et al. Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years［J］. Hepatogastroenterology, 2003, 50: 1362-1366.

［6］O’connor JP, Jackson A, Parker GJ, et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents［J］. Br J Cancer, 2007, 96: 189-195.

［7］Bajpai J, Gamanagatti S, Sharma MC, et al. Noninvasive imaging surrogate of angiogenesis in osteosarcoma［J］. Pediatr Blood Cancer, 2010, 54: 526-531.

［8］Wu X, Jeong EK, Emerson L, et al. Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers［J］. Mol Pharm, 2010, 7: 41-48.

［9］迟秀婷, 沈加林. 肝癌TACE治疗效果的影像学评估［J］. 介入放射学杂志, 2013, 22： 694-697.

［10］Jackson A. O’connor JP, Parker GJ. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging［J］. Clin Cancer Res, 2007, 13: 3449-3459.

［11］Zweifel M, Padhani AR. Perfusion MRI in the early clinical development of antivascular drugs:decorations or decision making tools［J］. Eur J Nucl Med Mol Imaging, 2010, 37(Suppl 1): S164-S182.

［12］Nationl Cancer Institute, National Institutes of Heatlth NCI CIP. MR workshop on translational research in cancer: recommendations for MR measurement methods at 1.5-Tesla and endpoints for use in phase 1/2a trials of anti-cancer therapeutics affecting tumor vascular function［EB/OL］. http://imaging.cancer.gov/reports and publications/Reports and Presentations/Magnetic Resonace Accessed, Aguust 20, 2008.

［13］Zwick S, Strecker R, Kiselev V, et al. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging［J］. J Magn Reson Imaging, 2009, 29: 1125-1133.

［14］Franiel T, Hamm B, Hricak H. Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer［J］. Eur Radiol, 2011, 21: 616-626.

［15］Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols［J］. J Magn Reson Imaging, 1999, 10: 223-232.

［16］Wilkinson ID, Jellineck DA, Levy D, et al. Dexamethasone and enhancing solitary cerebral mass lesions: alterations in perfusion and blood-tumor barrier kinetics shown by magnetic resonance imaging［J］. Neurosurgery, 2006, 58: 640-646.

［17］Oconnor JP, Carano RA, Clamp AR, et al. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging［J］. Clin Cancer Res, 2009, 15: 6674-6682.

［18］Guo CG, Zhang JF, Xu SL. Diffusion weighted imaging combined with dynamic contrast enhanced magnetic resonance imaging in monitoring therapeutic efficacy for hepatocellular carcinoma after transcatheter arterial chemoembolization［J］. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2014, 43: 77-82.

［19］Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations［J］. Br J Cancer, 2005, 92: 1599-1610.

［20］Chen BB, Shih TT. DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker［J］. World J Gastroenterol, 2014, 20: 3125-3134.

 

相似文献/References:

[1]王惠文,刘瑞宝,刘　　　岩,等.原发性肝癌ＴＡＣＥ后ＦＡＫ、ＮＦκＢｐ６５表达及意义[J].介入放射学杂志,2011,(08):621.
　WANG Hui-wen,LIU Rui-bao,LIU Yan,et al.The expression and significance of FAK and NF-κBp65 in hepatocellular carcinoma after transcatheter arterial chemoembolization[J].journal interventional radiology,2011,(06):621.
[2]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
　ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(06):78.
[3]王以浪,王亚非,张 亮,等. 肝细胞癌患者TACE术前后血清miR- 21表达变化及临床意义[J].介入放射学杂志,2014,(05):406.
　WANG Yi- lang,WANG Ya- fei,ZHANG Liang,et al. The changes of serum miR- 21 expression level in patients with HCC before and after TACE and its clinical significance[J].journal interventional radiology,2014,(06):406.
[4]尹芝兰,肖恩华.原发性肝癌行TACE术后对乙型肝炎病毒影响[J].介入放射学杂志,2014,(12):1114.
　YIN Zhi lan,XIAO En hua..The influence of TACE for primary hepatocellular carcinoma on hepatitis B virus[J].journal interventional radiology,2014,(06):1114.
[5]李 征,米登海,杨克虎,等.经动脉化疗栓塞联合微波消融治疗肝癌有效性和安全性的系统评价[J].介入放射学杂志,2015,(11):957.
　LI Zheng,MI Deng- hai,YANG Ke- hu,et al.Effectiveness and safety of TACE combined with MWA for primary hepatic cancer： a systematic review[J].journal interventional radiology,2015,(06):957.
[6]杨柏帅,施裕新,袁 敏,等.终末期肾衰竭肝癌患者TACE术中应用洛铂治疗3例[J].介入放射学杂志,2016,(05):381.
　YANG Bo- shuai,SHI Yu- xin,YUAN Min,et al.Transcatheter arterial chemoembolization using lobaplatin and lipiodol for the treatment of hepatocellular carcinoma associated with end- stage renal failure： report of three cases[J].journal interventional radiology,2016,(06):381.
[7]冯丽帅,马 旭,田庆华,等.微创介入技术治疗脊柱转移瘤的现状和展望[J].介入放射学杂志,2016,(08):738.
　FENG Li-shuai,MA Xu,TIAN Qing-hua,et al.Minimally-invasive interventional technique for the treatment of spinal metastases: current situation and prospect [J].journal interventional radiology,2016,(06):738.
[8]游建雄,王精兵,艾松涛,等.微球联合碘油栓塞治疗肝癌的近期疗效分析 [J].介入放射学杂志,2017,(06):531.
　YOU Jianxiong,WANG Jingbing,AI Songtao,et al.TACE by using microspheres and lipiodol for the treatment of hepatocellular carcinoma： analysis of short- term efficacy[J].journal interventional radiology,2017,(06):531.
[9]赵 倩,颜志平.载药微球经导管动脉化疗栓塞治疗肝癌研究进展 [J].介入放射学杂志,2017,(11):1052.
　ZHAO Qian,YAN Zhiping.Transarterial chemoembolization with drug- eluting beads for the treatment of hepatocellular carcinoma： recent progress in research[J].journal interventional radiology,2017,(06):1052.
[10]余晨曦,滕皋军.经导管动脉化疗栓塞术抵抗研究进展 [J].介入放射学杂志,2017,(12):1063.
　YU Chenxi,TENG Gaojun.Transarterial chemoembolization refractory： current research progress[J].journal interventional radiology,2017,(06):1063.

备注/Memo

备注/Memo:
（收稿日期：2015-12-16）


（本文编辑：俞瑞纲）
更新日期/Last Update: 2016-06-21